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CD40-targeted adenoviral GM-CSF gene transfer enhances and
prolongs the maturation of human CML-derived dendritic cells
upon cytokine deprivation
AGM Stam
1,5, SJAM Santegoets
1,5, TM Westers
2, CC Sombroek
1, JJWM Janssen
2, BW Tillman
4, AA van de
Loosdrecht
2, HM Pinedo
3, DT Curiel
3, GJ Ossenkoppele
2, RJ Scheper*,1 and TD de Gruijl
4
1Department of Pathology, Free University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands;
2Department of Hematology, Free
University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands;
3Division of Human Gene Therapy, Departments of Medicine,
Pathology, and Surgery and the Gene Therapy Center, University of Alabama at Birmingham, AL 35294, USA;
4Department of Medical Oncology, Free
University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Vaccination with autologous leukaemia-derived dendritic cells (DC) presents an adjuvant treatment option for chronic myeloid
leukaemia (CML). Here, we show that high-efficiency CD40-targeted adenoviral gene transfer of GM-CSF to CML-derived DC
induces long-lived maturation in the absence of exogenous cytokines and may thus ensure protracted stimulation of CML-specific T
cells upon vaccination.
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It has become clear from clinical observations that chronic
myeloid leukaemia (CML) is amenable to T-cell-mediated immune
surveillance (Kolb et al, 1995). An immunotherapeutic approach
may therefore provide a valuable adjuvant treatment option,
especially in minimal residual disease settings.
Leukaemic dendritic cells (DC), capable of eliciting T-cell
responses against CML targets (Choudhury et al, 1997; Eibl et al,
1997), are easily generated, carry all possible tumour antigens, and
can be used for autologous vaccination (Ossenkoppele et al, 2003).
Although it is still unclear how long DC should maintain their
mature phenotype and survive in vivo in order to generate an
effective antitumour T-cell response, it is generally accepted that a
stable mature DC phenotype is required to prevent reversion to a
possibly tolerogenic immature precursor state subsequent to
adoptive transfer. In this light, introduction of the gene encoding
granulocyte/macrophage-colony stimulating factor (GM-CSF) into
CML-DC may be an attractive approach to both enhance and
prolong antigen presentation and thus promote antileukaemic
responses (Thomas et al, 1998). Recombinant adenoviruses (Ad)
are attractive tools for gene transfer to DC, since they have been
reported to enhance the immunostimulatory capacity of DC
(Morelli et al, 2000). In addition, we previously reported that
retargeting Ad to CD40 on monocyte-derived DC (MoDC) through
a bispecific immunoconjugate could further increase DC matura-
tion and simultaneously enhance gene transfer (Tillman et al,
1999). Here, we report on the utility of CD40-retargeted Ad to
transduce CML-DC very efficiently, thereby reducing the viral dose
needed for the desired level of transgene expression and
simultaneously inducing phenotypic maturation as well as
enhanced functional activity of the CML-DC. Moreover, we show
that the introduction of GM-CSF into CML-DC by means of CD40-
targeted Ad can significantly prolong the stability of the mature
CML-DC phenotype.
MATERIALS AND METHODS
After informed consent, heparinised blood samples were collected
from patients with chronic-phase CML at diagnosis or during
treatment with hydroxyurea and/or IFN-a. PBMC were isolated
and CML-DC generated, phenotypically characterised, and tested
for leukaemic origin by bcr-abl FISH, as previously described
(Ossenkoppele et al, 2003).
Replication-deficient recombinant Ad-5 vectors and bispecific
Ad-targeting antibody conjugates were constructed, produced,
purified, and used for CML-DC infection as previously reported
(Tillman et al, 1999). The expression of green fluorescent protein
(GFP) and DC differentiation and maturation markers was
assessed by FACS, T-cell stimulatory capacity by allogeneic MLR,
and IL-12 p70 production by ELISA, all as described previously
(Tillman et al, 1999). For the assessment of GM-CSF production by
CML-DC (at 0.5 10
6ml
 1), supernatants were tested 24h
postinfection using an ELISA according to the manufacturer’s
specifications (Biosource Int., Camarillo, USA).
Transduction efficiencies (%), mean fluorescence intensities
(MF), and mean fluorescence Indices (MFI) were compared
between test conditions using a paired, two-tailed Student’s t-test.
Differences were considered significant when Po0.05.
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PBMC of chronic-phase CML patients were used to generate DC.
After 14–21 days culture in the presence of GM-CSF (100ngml
 1),
TNF-a (2.5ngml
 1), and IL-4 (1000Uml
 1), the cells displayed a
typical DC morphology. This was accompanied by de novo
expression of CD1a and CD80, and marked upregulation of
CD86, CD54, CD40, and HLA-DR (Figure 1A). To confirm the
leukaemic origin of the generated DC, cells were analysed for the
presence of the bcr-abl gene by FISH (Figure 1B).
FACS analysis showed the primary Ad docking receptor CAR to
be absent, but the avb3-integrin, facilitating Ad internalisation, to
be present on the cell surface of the CML-DC (data not shown). To
evaluate the susceptibility of CML-DC to Ad infection, CML-DC
were transduced with Ad encoding GFP (Ad-GFP) at MOI ranging
from 10 to 1000 plaque-forming units (PFU)/per cell. In line with
their lack of CAR expression, CML-DC were relatively resistant to
transduction with Ad, but transduction efficiencies and GFP
transgene expression levels could be significantly increased by
retargeting Ad to CD40 as an alternate docking receptor
(Figure 1C).
To evaluate whether CD40-retargeted Ad infection was accom-
panied by maturation of CML-DC, as we previously showed for
MoDC, we infected CML-DC with untargeted or CD40-targeted Ad,
and compared both their phenotype and function with uninfected
CML-DC, CML-DC infected by epidermal growth factor receptor
(EGFR)-retargeted Ad (using a control immunoconjugate), or
CML-DC infected by liposome-complexed Ad (lipofectamin-Ad),
which facilitated high-efficiency Ad infection comparable to CD40
retargeted Ad. As shown in Figure 2A, neo-expression of CD83 was
induced and the expression of CD54, CD86, and HLA-DR was
specifically enhanced upon CD40 targeting. These phenotypic
changes were accompanied by a significantly enhanced T-cell-
stimulatory capacity (Figure 2B) and the release of IL-12-p70
(Figure 2C).
To determine the combined effect of CD40 activation and GM-
CSF production on the maturation and the stability of the DC
phenotype over time, we transduced CML-DC with untargeted or
CD40-targeted Ad-GM-CSF or Ad encoding the carcinoma-
embryonic antigen as a control vector (Ad-CEA). The expression
of a panel of maturation molecules was evaluated at several time
points after infection. Optimal CML-DC activation was generally
measurable 3 days after CD40-retargeted Ad-GM-CSF transduction
and was only marginally higher as compared to the effects of
CD40-retargeted Ad-CEA transduction (not shown). However,
significantly elevated levels of CD40, CD80, CD86, and HLA-DR on
CML-DC transduced by CD40-targeted Ad-GM-CSF could be
maintained until days 7–14 as compared to CML-DC transduced
by untargeted Ad-GM-CSF or CD40-retargeted Ad-CEA
(Figure 2D). Indeed, without CD40-retargeted Ad-GM-CSF trans-
duction, levels of DC activation markers dropped to basal levels
within 7 days after cytokine deprivation (Figure 2D). Transduction
of CML-DC with Ad-GM-CSF complexed to liposomes, generally
resulting in equally high production levels of GM-CSF as with
CD40-retargeted Ad-GM-CSF, never resulted in a maintained high
expression of the DC activation markers (data not shown). Thus,
not high GM-CSF levels per se, but rather the combination of
CD40-mediated activation and GM-CSF production were respon-
sible for the observed maintenance of CML-DC maturation
subsequent to cytokine deprivation.
DISCUSSION
Our finding of an enhanced and prolonged mature phenotype
after transduction of CML-DC by CD40-targeted, Ad-mediated
GM-CSF gene transfer may have implications for CML-DC-based
immunotherapeutic approaches. Although previous studies
showed the ability of CML-DC to prime CML-specific cytotoxic
T lymphocytes (CTL) in vitro (Choudhury et al, 1997; Eibl et al,
1997), we were unable to detect any CTL responses in a
recently conducted clinical pilot study in which three IFN-a-
resistent CML patients in the late chronic phase of the disease
were vaccinated with autologous, in vitro generated immature
CML-DC (Ossenkoppele et al, 2003). In the same patients, we
did observe postvaccination DTH responses against both CML
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Figure 1 CML cells cultured with GM-CSF, IL-4, and TNF-a acquire DC
phenotype and retain their leukaemic origin. Targeting Ad to CD40 on
CML-DC significantly enhances gene transfer. (A) CML and CML-DC were
stained with fluorescein- or phycoerythrin-conjugated antibodies and
analysed by flow cytometry. CML-DC showed enhanced expression of
CD1a, CD40, CD54, CD80, CD86, and HLA-DR. Thin lines represent the
isotype control antibodies, bold lines represent staining with antibodies to
the indicated antigen. Similar results were noted for nine other patients. (B)
Cytospins were prepared from CML cells and CML-DC and an interphase
t(9;22) FISH was performed. Most CML-DC showed both red (bcr) and
green (abl) signals and one yellow (fused bcr-abl) signal (indicated by the
yellow triangles). Nuclei were stained blue by DAPI. The results for one
patient’s uncultured CML cells and the corresponding CML-DC after
culture (magnification  400) are shown. (C) CML-DC were infected with
Ad-GFP in the presence or absence of the Fab-anti-CD40 conjugate (a
bispecific immunoconjugate consisting of a chemically linked Fab fragment
of the S11 anti-Ad5 fibre knob mAb and the G28-5 anti-CD40mAb;
(Tillman et al. 1999). Cells were analysed by flow cytometry 48h after
infection; transduction efficiencies are given (in %) and the levels of GFP
expression are depicted as MF intensities. One representative experiment
out of four is shown. Significant differences were found for CD40-targeted
vs untargeted Ad at MOI 100, based on results from four separate
experiments; GFP transgene expression levels: *Po0.05, transduction
efficiency: **Po0.01.
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peripheral blood. These results showed the feasibility of raising
immune responses to CML through CML-DC-based vaccination,
even in the presence of a large tumour burden, but at the same
time indicated that the vaccine formulation needed to be optimised
in order to activate tumor-specific CTL effectively. Numerous
previous studies have pointed out the importance of proper DC
activation in order to obtain long-lasting CTL responsiveness in
vivo. Recent reports suggest that the use of immature DC for
vaccination can induce peripheral T-cell tolerance, either through
the induction of IL-10-producing regulatory T cells (Jonuleit et al,
2000), through the induction of T-cell anergy (Hawiger et al, 2001),
or even through the elimination of specific CTL clones (Kurts et al,
1997). In light of these observations, it seems important to ensure a
maintained mature phenotype of the adoptively transferred CML-
DC in order to avoid eventual tolerance induction. A critical step
in this context is the stimulation of immature DC by CD40L,
inducing phenotypic and functional maturation of DC, and
rendering DC capable of activating CTL (Schoenberger et al,
1998). The importance of this phenomenon for efficient tumour
rejection has been confirmed by in vivo studies and shown to
depend in large part on the production of IL-12 (van Mierlo et al,
2002). Our CD40-targeted approach of Ad transduction results
both in the upregulation of costimulatory and adhesion molecules
and in the release of IL-12, thus meeting the requirements for
tumor-specific CTL activation. In addition, the transduction of
CML-DC by CD40 targeted Ad vectors could serve as an ideal
means to introduce cytokine transgenes for the induction of a
more potent immune response and a prolonged survival of CML-
DC. CD40 retargeting of Ad and simultaneous GM-CSF gene
transfer resulted in a specific synergistic effect, characterised by
high GM-CSF production levels and the significant elevation and
prolonged expression of costimulatory and adhesion molecules on
CML-DC. This observation indicates a possible clinical utility of
CD40-retargeted Ad-GM-CSF transduction for the induction of a
mature T-cell stimulatory phenotype in CML-DC, which may be
expected to be stable over protracted periods of time after adoptive
transfer.
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Figure 2 CD40-targeted Ad transduction of CML-DC results in maturation. Introduction of the GM-CSF gene by this means leads to a prolonged mature
phenotype. CML-DC were incubated with the bispecific Fab-anti-CD40 conjugate or infected with Ad in the presence or absence of the Fab-anti-CD40
conjugate, a Fab-anti-EGFR control conjugate, or lipofectamin. (A) After 48h, transduced cells were stained with fluorescein- or phycoerythrin-conjugated
antibodies and analysed by flow cytometry. Thin lines represent the isotype control antibodies, bold lines represent staining with antibodies to the indicated
antigen. (B) After infection, transduced CML-DC were used as stimulator cells in an allogeneic MLR with 0.1 10
6 PBL per well as responder cells.
3H-
thymidine incorporation was measured at day 5 as a measure for proliferation. (C) Uninfected CML-DC or CML-DC infected by untargeted or CD40-
targeted Ad-GFP were cultured at 40000 cells per 200ml for 24h in the presence of 1000Uml
 1 IFN-g, after which IL-12 (p70) production was assessed in
the supernatants. Immature CML-DC (iCML-DC) or LPS-matured (for 1h at 100ngml
 1 LPS) CML-DC (mCML-DC) were thus tested. All results shown
are representative of at least three independent experiments. (D) CML-DC were infected with Ad-GM-CSF in the presence of Fab-anti-CD40 for 1h at
MOI 100 and compared to mock-infected DC, DC infected with (un)targeted AdCEA, or DC infected with untargeted Ad-GM-CSF. The expression of the
indicated activation markers was assessed at days 0, 7, 14, and 21 by staining with PE- or FITC-conjugated antibodies. Mean fluorescence indices for each
marker are depicted. Results from one representative experiment (out of five) are shown. Indicated statistically significant differences are based on data from
all five experiments: *Po0.05, CD40-targeted Ad-GM-CSF vs Ad-GM-CSF alone; **Po0.05, CD40-targeted Ad-GM-CSF vs CD40-targeted Ad-CEA;
***Po0.05, CD40-targeted Ad-GM-CSF vs both untargeted Ad-GM-CSF and CD40-targeted Ad-CEA. GM-CSF production levels were as follows (at 24h
postinfection, 5 10
5 CML-DC
 1ml, n¼5): control and Ad-CEA; undetectable; Ad-GM-CSF; 264pgml
 1; range 18–635pgml
 1; CD40-targeted Ad-
CEA, 138pgml
 1, range 0–274pgml
 1; CD40-targeted Ad-GM-CSF; 7798pgml
 1, range 2069–18446pgml
 1.
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